Skip to main content
Journal cover image

Economic Burden of Gefitinib Versus Pemetrexed for Insured Patients with Lung Cancer in Urban Xinjiang Province, China: A Real World Research

Publication ,  Conference
MAO, W; Chen, W
Published in: Value in Health
November 2016

Duke Scholars

Published In

Value in Health

DOI

ISSN

1098-3015

Publication Date

November 2016

Volume

19

Issue

7

Start / End Page

A887 / A887

Publisher

Elsevier BV

Related Subject Headings

  • Health Policy & Services
  • 4407 Policy and administration
  • 4203 Health services and systems
  • 3801 Applied economics
  • 1402 Applied Economics
  • 1117 Public Health and Health Services
 

Citation

APA
Chicago
ICMJE
MLA
NLM
MAO, W., & Chen, W. (2016). Economic Burden of Gefitinib Versus Pemetrexed for Insured Patients with Lung Cancer in Urban Xinjiang Province, China: A Real World Research. In Value in Health (Vol. 19, pp. A887–A887). Elsevier BV. https://doi.org/10.1016/j.jval.2016.08.264
MAO, W., and W. Chen. “Economic Burden of Gefitinib Versus Pemetrexed for Insured Patients with Lung Cancer in Urban Xinjiang Province, China: A Real World Research.” In Value in Health, 19:A887–A887. Elsevier BV, 2016. https://doi.org/10.1016/j.jval.2016.08.264.
MAO, W., and W. Chen. “Economic Burden of Gefitinib Versus Pemetrexed for Insured Patients with Lung Cancer in Urban Xinjiang Province, China: A Real World Research.” Value in Health, vol. 19, no. 7, Elsevier BV, 2016, pp. A887–A887. Crossref, doi:10.1016/j.jval.2016.08.264.
Journal cover image

Published In

Value in Health

DOI

ISSN

1098-3015

Publication Date

November 2016

Volume

19

Issue

7

Start / End Page

A887 / A887

Publisher

Elsevier BV

Related Subject Headings

  • Health Policy & Services
  • 4407 Policy and administration
  • 4203 Health services and systems
  • 3801 Applied economics
  • 1402 Applied Economics
  • 1117 Public Health and Health Services